Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trazodone for Prevention of Postpartum Depression
NCT05299398Phase 1Withdrawn
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in postpartum depression (PPD) comparing Trazodone with Placebo (2 arms). Primary endpoint: Occurrence of Major depressive episode at 27 weeks. Planned start Apr 2025; status: withdrawn.
02
Drugs
trazodone hydrochloride prolonged-release tablets
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT05299398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299398.